Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Kinnate Biopharma Inc. (Nasdaq: KNTE) has announced its participation in upcoming investor conferences in February 2021. CEO Nima Farzan will present at the Goldman Sachs West Coast Biotech Bus Tour on February 22, 2021, and the 10th Annual SVB Leerink Global Healthcare Conference on February 24, 2021. Both events are virtual, and investor meetings will also be hosted during the latter conference. A live webcast of the SVB Leerink presentation will be available on Kinnate's website, with a replay accessible for 30 days post-event.

SAN FRANCISCO and SAN DIEGO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that Nima Farzan, Chief Executive Officer of Kinnate, will provide a company overview at the following upcoming investor conferences in February:

• Event: Goldman Sachs West Coast Biotech Bus Tour
  Location: Virtual
  Date: Monday, February 22, 2021
  Time: 4:00-4:50 PM ET/1:00-1:50 PM PT

• Event: 10th Annual SVB Leerink Global Healthcare Conference
  Location: Virtual
  Date: Wednesday, February 24, 2021
  Time: 4:20 PM ET/1:20PM PT

Members of the Kinnate management team will also host investor meetings during the SVB Leerink Global Healthcare Conference.

A live webcast of the SVB Leerink presentation will be available in the Investors and Media section of the Kinnate website at www.kinnate.com. A webcast replay will also be available on this website shortly after conclusion of the event for 30 days.

About Kinnate Biopharma Inc.
Kinnate is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Kinnate’s mission is to expand the reach of targeted therapeutics by developing products for underserved populations. Kinnate utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine, which it refers to as the Kinnate Discovery Engine, to develop targeted therapies. Based in San Francisco and San Diego, California, the Kinnate team is composed of drug discovery experts supported by a distinguished group of scientific advisors. For more information, please visit www.kinnate.com.

Forward Looking Statements
This press release contains forward-looking statements, as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, without limitation, Kinnate’s expected participation at investor conferences. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Such expectations and projections may never materialize or may prove to be incorrect. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties, assumptions and other factors described under the heading “Risk Factors” in our Form S-1 Registration Statement that we have filed with the Securities and Exchange Commission (the “SEC”) and that became effective on December 2, 2020, as well as in our subsequent filings we make with the SEC. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. Investors should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this press release.

Contacts:

Investors:
Patti Bank
Westwicke, an ICR Company
415-513-1284
investors@kinnate.com

Media:
Colin Sanford
colin@bioscribe.com

FAQ

What investor conferences will Kinnate Biopharma participate in February 2021?

Kinnate Biopharma will participate in the Goldman Sachs West Coast Biotech Bus Tour on February 22, 2021, and the 10th Annual SVB Leerink Global Healthcare Conference on February 24, 2021.

When is Kinnate's presentation at the Goldman Sachs Biotech Bus Tour?

Kinnate's presentation at the Goldman Sachs West Coast Biotech Bus Tour is scheduled for February 22, 2021, from 4:00 to 4:50 PM ET.

Will there be a webcast for Kinnate's presentations at the investor conferences?

Yes, a live webcast of Kinnate's presentation at the SVB Leerink Global Healthcare Conference will be available on their website, along with a replay for 30 days after the event.

Who is the CEO of Kinnate Biopharma?

The CEO of Kinnate Biopharma Inc. is Nima Farzan.